Clinical Trial: Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07450183) titled 'Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1' on Feb. 16.

Brief Summary: This is a single arm phase II trial enrolling patients with stage II-IIIA non-small cell lung cancer whose disease is deemed amenable for surgical resection and has a PD-L1 level of >=50%. Patients will receive cemiplimab for 3 cycles followed by surgical resection. The primary endpoint evaluated by the study is the amount of residual tumor in the resected tissue after 3 cycles of cemiplimab. After surgery, all patients will receive additional 10 cycles of cemiplimab and the treating oncologist will decide on the need of ad...